Of 439 European-American participants enrolled in the Fast Track RCT, 62 percent (n=270) provided a DNA sample that was successfully genotyped at NR3C1; 90 percent (N=242) of this genetic sample were interviewed at age 25 (Treatment n=114; Control n=128). Attrition analyses comparing the analytic sample of N=242 to the complete European-American Fast Track sample of N=439 on the pre-intervention severity-of-risk score used to screen children into the Fast Track RCT (see Figure 1 caption for details) found no statistically significant differences between the full Fast Track sample and the analytic sample for either treated or control children (p-values>0.835). Pre-intervention severity-of-risk score did not differ between control and treated children within the analytic sample (p=0.237).
